Tag: sputnik

Shares of Panacea Biotec surged 9 percent to Rs 411 on the BSE in the intra-day trade on Monday after the company announced that it has received a manufacturing license to produce Sputnik V vaccine at its Baddi (Himachal Pradesh) plant, after the first batch of the covid-19 vaccine cleared all quality-control tests at the Gamaleya Center, Russia, the company said. “Panacea Biotec is delighted to announce the obtaining of the manufacturing license to produce Sputnik V vaccine in India. On this occasion, we thank the leadership of our Hon’ble Prime Minister Modi Ji and Government of India for timely handholding and expediting clearances to enable ‘Make in India’ vaccines," said Dr. Rajesh Jain, Managing Director, for Panacea Biotec. Sputnik V has been part of India’s covid vaccination drive since 14 May after receiving the emergency use authorization on 12 April. Sputnik V has been registered in 67 countries globally, covering a total population of over 3.5 billion people. Read more

Russia’s Covid-19 vaccine Sputnik V launched in India on Friday, with the first dose being administered in Hyderabad. The price of the imported vaccine is priced at a maximum retail price of Rs 948, with 5 percent GST per dose, amounting to Rs 995.4 per dose. Dr. Reddy's Laboratories (DRL), the Indian distribution partner for the vaccine, said that the first consignment of the imported doses landed in India on May 1 and received regulatory clearance from the Central Drugs Laboratory, Kasauli, on May 13. Dr Reddy's on May 14 said it plans to vaccinate 125 million people in the next 8-12 months with the Sputnik vaccine. About 15-20 percent of the initial supplies would be imported from Russia."With the rising cases in India, vaccination is the most effective tool in our battle against COVID-19. Contributing to the vaccination drive in India is our biggest priority right now to help Indians be healthy and safe," said G V Prasad, co-chairman and Managing Director of DRL. Read more

Shares of Dr Reddy’s Laboratories gained by 8 per cent to Rs 5,119.90 on the BSE in intra-day trade on Monday after Sputnik-V, the vaccine against the coronavirus disease (Covid-19), got the nod from the expert panel for emergency use in India. The Subject Expert Committee (SEC) advising the Drug Controller General of India (DCGI) has recommended Russia's Sputnik V for emergency use authorisation in India. This is the third vaccine approved by India after Covishield and Covaxin

Shares of Panacea Biotec were locked in the upper circuit of 20 per cent at Rs 220.85 on the BSE in Tuesday's session after the company and the Russian Direct Investment Fund (RDIF) agreed to produce 100 million doses of Sputnik V vaccine in India per year.Production of Sputnik V at Panacea Biotec sites will help facilitate the global supply of Sputnik V to international partners of RDIF, a joint statement said.Panacea Biotec will produce Sputnik V in its internationally accredited facilities complying to strict GMP standards and prequalified by the World Health Organization (WHO), he added. Efficacy of Sputnik V is 91.6 per cent as confirmed by the data published in the Lancet, one of the world's oldest and most respected medical journals," the release said.